🚨 European Commission approval alert ! ✅ Servier’s Voranigo (vorasidenib) approved for patients with a specific type of brain tumour, becoming the first targeted therapy for Grade 2 IDH-mutant glioma. 📊 Approval supported by clinical trial data showing significant improvement in PFS vs placebo.

Struggling with decisions on asparaginase therapy?" Dr Anthony Perissinotti explains how the ONCOassist SAA Tool takes the guesswork out of interpreting serum asparaginase activity levels 💉 📺 Watch Now: youtu.be/LE1qxG52sno 🌐 Learn more at: oncoassist.com

🚨BREAKING: FDA authorizes CytoCell KMT2A Breakapart FISH Probe Kit PDx as a new companion diagnostic for KMT2A-rearranged acute leukemia. 👉 Approved as CDx for Syndax’s REVUFORJ® (revumenib), the first-in-class menin inhibitor for R/R acute leukemia with KMT2A translocation. bit.ly/ONCOnews23SEP-1

🚨Japan Regulatory Update! ✅ Nuvation Bio’s IBTROZITM (taletrectinib) approved by Japan’s Ministry of Health, Labour and Welfare for advanced ROS1-positive NSCLC ➡️ Based on pivotal Phase 2 TRUST studies showing high, durable response rates 🔗 Read more: bit.ly/ONCOnews22S-3

🚨BREAKING: Positive Phase III Results! 📈 Roche’s giredestrant + everolimus significantly improved progression-free survival in ER-positive advanced breast cancer, including ESR1-mutated patients, post-CDK inhibitor. 🔗 Read more: bit.ly/ONCOnews22S-2

🚨FDA Approval Alert ! ✅ The FDA has approved Merck’s KEYTRUDA QLEX™ (pembrolizumab + berahyaluronidase alfa-pmph) for subcutaneous use in adults across most solid tumor indications for KEYTRUDA® (pembrolizumab). 🔗 bit.ly/ONCOnews22S-1 #ONCOnews #OncoAlert #OncEd #FDAApproval #Immunotherapy

🚨BREAKING: 📢 Deciphera’s ROMVIMZA™ (vimseltinib) Receives European Commission Approval ✅ Approved for the treatment of Tenosynovial Giant Cell Tumor (TGCT), offering a new option for patients with this rare condition. 🔗 Read more: bit.ly/ONCOnews18S-2

🚨BREAKING: Low-Dose Aspirin in PI3K-Altered Localized Colorectal Cancer 🩺 Aspirin has shown potential to reduce adenomas & improve disease-free survival in patients with PIK3CA-mutated tumors. ⚠️ Randomized trial data are still awaited. 🔗 Read more: bit.ly/ONCOnews18S-1

Access 11 Elderly Frailty Screening Tools in seconds with ONCOassist. #ONCOassist #FrailtyScreening #G8Tool #GeriatricOncology #OncologyTools #GeriatricOncology #CARG #ElderlyCare

📢 New Guideline Alert: 🩺 ASTRO-ASCO-SSO release updated clinical practice guideline on Postmastectomy Radiation Therapy (PMRT) in breast cancer Key updates: 🔹 Indications for PMRT after surgery & neoadjuvant therapy 🔹 Guidance on target volumes, dosing & techniques 🔗 bit.ly/ONCOnews17S-1

🚨 FDA approval alert! 🧬 Biocartis secures FDA approval for the Idylla™ CDx MSI Test ✅ First fully automated, sample-to-result, cartridge-based companion diagnostic in the US for colorectal cancer patients. 🔗 Read more: bit.ly/ONCOnews16S-2 #ONCOnews #OncoAlert #OncEd #ColorectalCancer

🚨BREAKING: Novocure’s Optune Lua® approved in for unresectable advanced/recurrent #NSCLC. ✅ Can be used with PD-1/PD-L1 inhibitors after platinum chemo 📊 Backed by Phase 3 LUNAR trial, showing significant OS benefit 🔗 Read more: bit.ly/ONCOnews16S-1

🚨BREAKING: Phase III MARIPOSA (Asia Cohort) 🫁 RYBREVANT® (amivantamab-vmjw) + LAZCLUZE® (lazertinib) shows statistically significant OS benefit vs osimertinib in EGFR-mutated NSCLC 💊First & only chemo-free combo in 1L setting with survival gains of this magnitude 🔗 Read more:bit.ly/ONCOnews15S-1

🚨Phase III PREOPANC-2 Trial ! ✅ Neoadjuvant FOLFIRINOX (FFX) vs gemcitabine-based chemoradiotherapy in resectable & borderline resectable pancreatic ductal adenocarcinoma (PDAC). 📈 FFX demonstrated improved OS compared with gemcitabine-CRT followed by adjuvant gemcitabine. 🔗 bit.ly/ONCOnews12S-1

🚨 FDA Approval Alert ! ✨The FDA has approved Koselugo (Selumetinib) for children ≥1 year with NF1 & symptomatic, inoperable plexiform neurofibromas 🔬 Approval supported by bridging + exposure-matching data from the SPRINT & SPRINKLE studies. 🔗 Read more: bit.ly/ONCOnews11S-1

🚨 FDA Approval Alert ! ✅ The FDA has approved the gemcitabine intravesical system for adults with BCG-unresponsive NMIBC with CIS, with or without papillary tumors. 💊 The system is co-packaged with a urinary catheter and stylet for direct bladder delivery. 🔗 Read more: bit.ly/ONCOnews10S-2

Calculate Corrected QT Interval (QTc) in 17 seconds with ONCOassist #QTc #CorrectedQT #ONCOassist #OncologyTools #Cardiotoxicity #DigitalHealth #ClinicalCalculators #QTcBazett #QTInterval #MedTech

🔔 New Data at IASLC 2025 World Conference on Lung Cancer: 🚀 New 5-year data show Libtayo® (cemiplimab) + chemo delivers significant & lasting survival benefits in advanced NSCLC 📊 5-year OS: 19.4% vs 8.8% (chemo alone) 🫁 Squamous NSCLC: Median OS 22.3 months 🔗 Read more: bit.ly/ONCOnews10S-1

🚨New in #Oncology! 💉NADIM ADJUVANT Interim Data: Adjuvant chemo-IO may lower recurrence risk after complete resection in Early-stage NSCLC. 🧾 Dr. Mariano Provencio: Findings could help define a new standard adjuvant treatment, though longer follow-up is needed. 🔗 Read more: bit.ly/ONCOnews9S-5

🚨New in #Oncology! 🧪 COMPEL Trial: Osimertinib + chemo outperformed chemo alone in EGFRm NSCLC after progression. 📈 Dr. Giulia Pasello: Combo showed improved median PFS, despite being underpowered. 🔗 Read more: bit.ly/ONCOnews9S-4 #ONCOnews #OncoAlert #OncEd #LungCancer #NSCLC #ClinicalTrials

🚨BREAKING: ANKTIVA® (nogapendekin alfa inbakicept-pmln) in Advanced NSCLC! 💉 First FDA-approved lymphocyte-stimulating agent 📊 Reversed severe lymphopenia — 80% of patients maintained ALC >1,000 cells/µL 🔗 Read more: bit.ly/ONCOnews9S-3 #ONCOnews #OncoAlert #OncEd #LungCancer #NSCLC

🚨New in #Oncology! 🧬 Cellworks reveals that combining TME + TLS dynamics can better predict patient-level response to immunotherapy. ⚡ Novel model shows meaningful survival differences in checkpoint inhibitor–treated patients. 🔗 Read more: bit.ly/ONCOnews9S-2 #ONCOnews #OncoAlert #OncEd #NSCLC

🚨 New in #Oncology! 💊 Lilly’s Jaypirca (pirtobrutinib), the 1st & only non-covalent BTK inhibitor 📈 Significantly improves progression-free survival in treatment-naïve patients. 🔗 Read more: bit.ly/ONCOnews9S-1 #ONCOnews #OncoAlert #OncEd #Leukemia #Lymphoma

🚨New in #Oncology! ✅ Phase III HARMONi trial: Longer-term Western patient follow-up shows an improving OS trend 💊 Ivonescimab + Chemo demonstrates benefit in 2L+ EGFRm NSCLC 🔗 Read more: bit.ly/ONCOnews8S-4 #ONCOnews #OncoAlert #OncEd #LungCancer #NSCLC

🚨New in #Oncology! 📢 PORTEC-3 Phase III trial reports 10-year outcomes in women with high-risk endometrial cancer. 🔬Adjuvant chemoradiotherapy vs radiotherapy alone + post-hoc molecular classification analysis provides key insights for treatment decisions. 🔗 bit.ly/ONCOnews8S-3 #ONCOnews

🚨New in #Oncology! 🫁 Final OS results awaited from the Phase III trial of Amivantamab + Lazertinib in EGFR-mutated advanced NSCLC. ⏳ Earlier data showed significantly improved PFS in this combination vs Osimertinib. 🔗bit.ly/ONCOnews8S-2 #ONCOnews #OncoAlert #OncEd #CancerResearch #ClinicalTrial

🚨New in #Oncology! 🫁 Tagrisso (Osimertinib) + chemo delivers nearly 4 years overall survival, the longest ever reported in EGFRm advanced lung cancer. 👉 FLAURA2 confirms its role as the 1st-line standard of care & backbone therapy. 🔗 Read more: bit.ly/ONCOnews8S-1 #ONCOnews #OncoAlert #OncEd

🚨New in #Oncology! ✅ Agilent’s MMR IHC Panel pharmDx(Dako Omnis) receives European IVDR Certification 🌍 Approved as a Companion Diagnostic for Colorectal Cancer — advancing precision oncology across Europe 🔗 bit.ly/ONCOnews3S-1 #ONCOnews #OncoAlert #OncEd #CancerDiagnostics #ColorectalCancer

📲 Calculate PSA Doubling Time in under 30 seconds with ONCOassist #ONCOassist #PSADoublingTime #ProstateCancer #Urology #OncologyTools #DigitalHealth #ClinicalCalculator #CancerMonitoring #OncologyApp

🚨Breaking News: 🔬EMA grants Orphan Drug Designation to OXC-101 for acute myeloid leukemia (AML) ✅ Follows earlier FDA ODD approval, expanding recognition across US & EU. 🔗 Read more: bit.ly/ONCOnews2S-3 #ONCOnews #OncoAlert #OncEd #Oncology #DrugDevelopment

🚨 New in #Oncology! ✅ Zai Lab’s TIVDAK® (tisotumab vedotin-tftv) approved in Hong Kong for recurrent or metastatic cervical cancer after chemotherapy progression. 🔑 Expands treatment options for patients facing advanced cervical cancer. 🔗 bit.ly/ONCOnews2S-2 #ONCOnews #OncoAlert #OncEd

🚨 In this clip, Dr. Paul O’Brien outlines what AI can do in oncology and what’s holding it back. 🎥 Watch now: youtu.be/G94C7h_bmkk #OncologySpotlight #DrPaulOBrien #AIinMedicine #HealthcareAI #EHR #ONCOassist

🚨 FDA Approval alert! 🩸Sanofi’s Wayrilz (rilzabrutinib) becomes the first BTK inhibitor approved in the US for immune thrombocytopenia (ITP) ✅ Based on Phase III LUNA 3 trial: rapid & durable platelet response + symptom improvements 🔗 Read more: bit.ly/ONCOnews2S-1 #ONCOnews #OncoAlert #OncEd

🚨New in #Oncology! 🧬 Novotech supports approval of Anlotinib combo therapy for advanced soft tissue sarcoma 💊 📊 Phase III trial showed a 5.6-month improvement in median PFS, marking a major step forward in treatment options. 🔗 bit.ly/ONCOnews29AU-1 #ONCOnews #OncoAlert #OncEd #Sarcoma

🚨 Regulatory Update! ✅ European Commission approves TEVIMBRA® (tislelizumab) as neoadjuvant/adjuvant treatment for NSCLC 🫁 📊 Approval comes ahead of late-breaking data presentation at WCLC 2025 🔗 Read more: bit.ly/ONCOnews28AU-4 #ONCOnews #OncoAlert #OncEd #LungCancer #Oncology #CancerResearch

🚨New in #Oncology! 🌍 ASCO issues its first guideline on cancer-specific geriatric assessment for older patients in resource-limited settings 📌 Focused on patients 65+ with cancer, receiving treatment in countries with limited resources. 🔗 bit.ly/ONCOnews28AU-3 #ONCOnews #OncoAlert #OncEd

🚨 BREAKING: ✨ Lilly’s Verzenio® (abemaciclib) + endocrine therapy shows a significant & clinically meaningful OS benefit vs endocrine therapy alone ✅ Proven benefit in HR+, HER2-, high-risk early breast cancer with 2 years of therapy 🩺 🔗 bit.ly/ONCOnews28AU-2 #ONCOnews #OncoAlert #OncEd

🚨 Clinical Trial Update! ✅ Phase 3 HERTHENA-Breast04 trial, co-conducted by Merck & Daiichi Sankyo, has launched to evaluate patritumab deruxtecan. 🔬💊 🎯 Focus: Metastatic HR+ / HER2– breast cancer patients previously treated with endocrine therapy 🔗 bit.ly/ONCOnews28AU-1 #ONCOnews #OncoAlert

🚨 FDA Breakthrough Therapy Designation ! ✅ Genmab’s Rina-S® (rinatabart sesutecan) earns designation for advanced EC ✨ Rina-S® is designated for adults with recurrent/progressive endometrial cancer and will advance to a Phase 3 trial 🔬 🔗 bit.ly/ONCOnews27AU-1 #ONCOnews #OncoAlert #OncEd

The NCCN Distress Thermometer is now in ONCOassist. Access it now. 0–10 scale + Problem List = better support. #ONCOassist #DistressThermometer #PsychosocialOncology #CancerCare #OncologyTools #NCCN #OncologyTools #Oncologists

🚨 Regulatory Update! ✅ China’s NMPA approves Datroway (datopotamab deruxtecan) from Daiichi Sankyo & AstraZeneca for HR+ / HER2– metastatic breast cancer 📊 Backed by Phase III TROPION-Breast01 trial results 🔗 Read more: bit.ly/ONCOnews26AU-1 #ONCOnews #OncoAlert #OncEd #BreastCancer #Oncology

🚨 Dr. Douglas Flora shares how he uses GPT, Gemini, Copilot & more to save time and stay focused on patient care. 📺 Watch the clip: youtu.be/QUEwOkcABqg #AIinOncology #ONCOassist #DigitalHealth #OncologyTools #MedTech #GPTinMedicine

🚨New in #Oncology! ✅ FDA Approval Summary: 📌 Inavolisib + Palbociclib + Fulvestrant - approved for endocrine-resistant, PIK3CA-mutated HR+/HER2– locally advanced or metastatic breast cancer. 🔗 Read more: bit.ly/ONCOnews25AU-1 #ONCOnews #OncoAlert #OncEd #BreastCancer #PrecisionMedicine

🚨New in #Oncology! ✅ The European Commission approves tablet formulation of BRUKINSA® (Zanubrutinib) for all approved indications. 💊 A step forward in treatment simplicity & convenience, enhancing patient care across Europe. 🔗 bit.ly/ONCOnews22AU-3 #ONCOnews #OncoAlert #OncEd #CancerResearch

🚨New in #Oncology! 📊 New insights from the BWEL trial: A weight loss intervention in women with stage II/III breast cancer shows impact on 1-year weight change. ➡️ Secondary analysis highlights the role of lifestyle in cancer outcomes. 🔗 bit.ly/ONCOnews22AU-2 #ONCOnews #OncoAlert #OncEd

🚨New in #Oncology! ✅ Health Canada approves Columvi® (Glofitamab, Roche), First bispecific antibody in Canada 🧬 Indicated for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after initial therapy 🔗 Read more: bit.ly/ONCOnews22AU-1 #ONCOnews #OncoAlert #OncEd #Lymphoma #CancerResearch

🚨New in #Oncology! ✨ Health Canada approves OPDIVO® (Nivolumab) + YERVOY® (Ipilimumab) dual immunotherapy for CRC and HCC. 🧩 New 1L option for unresectable/metastatic MSI-H/ dMMR CRC 🩸 Approved for unresectable/advanced HCC 🔗bit.ly/ONCOnews21AU-1 #ONCOnews #OncoAlert #OncEd #ColorectalCancer

🧮 Calculate corrected calcium in under 15 seconds with ONCOassist #Oncology #CorrectedCalcium #ONCOassist #ClinicalTools #DigitalHealth #OncologyCalculator #MedTech #MedTwitter #OncoDaily

🚨New in #Oncology! Final Analysis of Phase III KEYNOTE-585 results! 📊 Pembrolizumab + chemotherapy improves outcomes vs chemo alone as perioperative therapy in locally Advanced Gastric & Gastroesophageal Junction Cancer. 🔗 bit.ly/ONCOnews20AU-1 #ONCOnews #OncoAlert #OncEd #Immunotherapy

🚨 New in #Oncology! 💡 Phase III IMvigor011 trial in muscle-invasive bladder cancer reports positive results. 📊 Signatera™ ctDNA MRD–guided approach strongly predicts benefit from adjuvant Atezolizumab (Tecentriq®). 🔗 Read more: bit.ly/ONCOnews19AU-3 #ONCOnews #OncoAlert #OncEd #BladderCancer